Valuation stretched; downgraded the stock Dr. Lal PathLabs Ltd provides diagnostic and related...
DLPL reported high single digit revenue growth with very strong EBITDA margin of 27% (350bps beat...
DLPL reported 4Q numbers with mid-teens non-Covid growth (incl. Suburban) with better than expect...
India's Dr. Lal PathLabs Ltd on Thursday reported a sixth consecutive fall in quarterly profi...
We recently hosted the management of Fusion Micro Finance for an NDR. Management reiterated its f...
We attended GAIL’s analyst meet today. During the interaction, the management highlighted t...
We visited CEAT’s Halol plant, its largest PCR and TBR plant in India. Company’s focu...
Axis Bank today completed the acquisition of Citibank's consumer businesses in India (announc...
Jindal Steel and Power (JSP) has undergone a significant transformation over the past few years, ...
Suburban execution key to West expansion We visited Suburban’s new state-of-the-art Vidy...
Dr. Lal Pathlabs is currently trading at Rs. 1851.40, up by 16.15 points or 0.88% from its previo...
Weak volume outlook Result Synopsis Dr Lal reported a weak revenue quarter as growth declin...
Key News Dr Lal PathLabs Q3 net down 7% to Rs 54 cr, revenue declines to Rs 489 cr: Dr Lal ...
Dr. Lal Pathlabs is currently trading at Rs. 2077.40, up by 17.35 points or 0.84% from its previo...
Shares of the healthcare service providers are trading higher, as Union Minister of Health and Fa...
Margins improve despite slow growth Dr Lal Pathlabs’ (Dr Lal) Q2FY23 performance was a m...
Margin surprise highlights core strength Dr Lal PathLabs (‘DLPL’) reported 15%YoY ...
In?line quarter; near?term pressure remain DLPL reported&...
Indian medical diagnostics firm Dr. Lal PathLabs Ltd on Tuesday reported a 24.5% drop in Septembe...
The company reported standalone net profit of Rs 79.60 crore for the quarter ended June 30, 2022 ...
Dr. Lal Pathlabs is currently trading at Rs. 1933.10, down by 120.05 points or 5.85% from its pre...
Margin woes may not be structural Result Synopsis Dr Lal 4Q revenues were up 13%, slightly ...
Business Overview Dr Lal PathLabs (DLPL) is the largest diagnostics player in India. Its domin...
Key News Union Bank of India looks to move to a new tax regime in FY23 Union Bank of India ...
Suburban acq. overshadows an inline Q Our view Acquisition of Suburban Diagnostics overshad...
Below is quote on Dr. Lal Path labs acquisition of Suburban Diagnostics for ₹1150 crores&nbs...
Below are Views On India’s largest diagnostics chain unfazed by disruptors By Dr Om Ma...
Hold Dr Lal Pathlabs Ltd For Target Rs.3,405 COVID driven upside; base business steady Dr L...
Significant rise in COVID testing Dr. Lal PathLabs Limited (DLPL) provides diagnostic and rela...
Dr. Lal Pathlabs is currently trading at Rs. 4011.10, up by 278.60 points or 7.46% from its previ...
Industry leading performance continues Dr Lal Pathlabs’ (Dr Lal) Q4FY21 performance was ...
Result Highlights * 43% jump in Q4 sales on YoY rebound in non COVID business on low base of l...
Our Take: Dr Lal PathLabs (DLPL) is a leading player in the highly fragmented and c...
Maintains superior execution Dr Lal Pathlabs’ (Dr Lal) Q3FY21 performance was above est...